Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Leukemia (8)
Blood Cancer Journal (8)
Nature Medicine (1)
Scientific Reports (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (11)
Correspondence (7)

Subject Check one or more subjects to show results from those subjects only.

Biomarkers
Cancer
Diseases
Health care
Medical research
Molecular medicine
Oncology
Pathogenesis
Risk factors

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–18 of 18 results

Advanced filters: Author: Alberto Alvarez-Larran Clear advanced filters

European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis

Monia Marchetti
Alessandro Maria Vannucchi
Tiziano Barbui
ResearchOpen Access24 Nov 2025
Blood Cancer Journal

Volume: 15, P: 1-6
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

In a randomized phase 3 trial, the combination of the BET inhibitor pelabresib with the JAK inhibitor ruxolitinib resulted in a significantly higher spleen volume reduction from baseline versus placebo with ruxolitinib in patients with JAK inhibitor-naive myelofibrosis.

Raajit K. Rampal
Sebastian Grosicki
John Mascarenhas
ResearchOpen Access10 Mar 2025
Nature Medicine

Volume: 31, P: 1531-1538
Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera

Miguel Piris-Villaespesa
Alberto Álvarez-Larrán
Valentin Garcia-Gutierrez
ResearchOpen Access08 Jan 2021
Scientific Reports

Volume: 11, P: 1-7
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

Irene Pastor-Galán
Arturo Pereira
Juan Carlos Hernández-Boluda
Research30 Aug 2024
Leukemia

Volume: 38, P: 2483-2486
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients

Tiziano Barbui
Valerio De Stefano
John Mascarenhas
Research19 May 2021
Leukemia

Volume: 35, P: 2989-2993
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui
Alessandro Maria Vannucchi
Alessandro Rambaldi
Research07 Jan 2021
Leukemia

Volume: 35, P: 485-493
Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea

Alberto Alvarez-Larrán
Alvaro Díaz-González
Juan Carlos Hernández-Boluda
ResearchOpen Access05 May 2020
Leukemia

Volume: 35, P: 623-627
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

Tiziano Barbui
Valerio De Stefano
Alessandro Maria Vannucchi
ResearchOpen Access04 Feb 2021
Blood Cancer Journal

Volume: 11, P: 1-11
Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

Marta Santaliestra
Marta Garrote
Alberto Alvarez-Larrán
Research27 Sept 2024
Leukemia

Volume: 38, P: 2636-2643
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Tiziano Barbui
Arianna Ghirardi
Guido Finazzi
Research29 May 2019
Leukemia

Volume: 33, P: 1996-2005
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

Juan Carlos Hernández-Boluda
Arturo Pereira
Juan Luis Steegmann
ResearchOpen Access02 Dec 2018
Blood Cancer Journal

Volume: 8, P: 1-8
Breakthrough infections in MPN-COVID vaccinated patients

Tiziano Barbui
Alessandra Carobbio
Alessandro Maria Vannucchi
CorrespondenceOpen Access15 Nov 2022
Blood Cancer Journal

Volume: 12, P: 1-6
Second versus first wave of COVID-19 in patients with MPN

Tiziano Barbui
Alessandra Iurlo
Alessandro Maria Vannucchi
Correspondence21 Jan 2022
Leukemia

Volume: 36, P: 897-900
Long-term follow-up of recovered MPN patients with COVID-19

Tiziano Barbui
Alessandra Iurlo
Alessandro Rambaldi
CorrespondenceOpen Access16 Jun 2021
Blood Cancer Journal

Volume: 11, P: 1-4
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

Lucía Pérez-Lamas
Adrián Segura Diaz
Valentín García Gutiérrez
CorrespondenceOpen Access17 Apr 2025
Blood Cancer Journal

Volume: 15, P: 1-6
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score

Tiziano Barbui
Arianna Ghirardi
Alessandro Maria Vannucchi
CorrespondenceOpen Access16 Nov 2022
Blood Cancer Journal

Volume: 12, P: 1-4
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Valentín Garcia-Gutiérrez
Alejandro Luna
Juan Carlos Hernández-Boluda
CorrespondenceOpen Access09 Feb 2021
Blood Cancer Journal

Volume: 11, P: 1-4
Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

Tiziano Barbui
Arianna Ghirardi
Alessandro Rambaldi
Correspondence07 Nov 2019
Leukemia

Volume: 34, P: 1208-1209